One To Watch

Tenaya Therapeutics

A clinical-stage biotechnology company developing gene and regenerative therapies for genetic and acquired heart diseases. Tenaya Therapeutics focuses on treatments designed to address the underlying molecular causes of cardiomyopathies rather than managing symptoms.

Company Overview

Tenaya Therapeutics develops medicines intended to treat heart disease at the genetic or cellular level. The company’s pipeline includes gene therapies and regenerative approaches aimed at correcting disease-causing mutations or restoring cardiac function.

Its strategy combines gene therapy, cellular regeneration and precision-medicine programs targeting specific genetic forms of cardiomyopathy.

Headquarters and Global Presence

Tenaya Therapeutics is headquartered in South San Francisco, California, United States.

The company conducts clinical development through global trial networks and collaborates with academic cardiovascular research centers.

Founding and History

Tenaya Therapeutics was founded in 2016 by cardiovascular scientists Bruce Conklin and Benoit Bruneau.

The company was established to translate advances in cardiac genetics and regenerative biology into therapeutic programs. Tenaya later completed an initial public offering in 2021 to fund development of its gene-therapy pipeline.

Therapy Areas and Focus

Tenaya’s research programs focus on genetic and degenerative heart diseases.

Key areas include:

Hypertrophic cardiomyopathy
Arrhythmogenic right ventricular cardiomyopathy
Dilated cardiomyopathy
Heart failure and related cardiovascular disorders

These conditions often arise from inherited mutations that disrupt cardiac muscle function.

Technology Platforms and Modalities

Tenaya develops therapies across several cardiovascular-focused technology platforms.

Key modalities include:

Adeno-associated virus (AAV) gene therapies
Cardiac regeneration approaches
Precision-medicine small molecules targeting heart-failure pathways

The company’s goal is to correct or compensate for the molecular defects that drive cardiomyopathy.

Key Pipeline Programs

Selected programs include:

TN-201, an AAV9 gene therapy designed to deliver a functional MYBPC3 gene for patients with MYBPC3-associated hypertrophic cardiomyopathy; currently in Phase I b/II clinical testing.
TN-401, an AAV9 gene therapy targeting PKP2 mutations in arrhythmogenic right ventricular cardiomyopathy.
TN-301, a small-molecule program targeting heart failure with preserved ejection fraction through modulation of the DWORF pathway.

Key Personnel

Faraz Ali, Chief Executive Officer
Bruce Conklin, Co-Founder and Scientific Advisor
Benoit Bruneau, Co-Founder and Scientific Advisor

Strategic Partnerships

Tenaya collaborates with academic and industry partners to advance its cardiovascular pipeline.

These collaborations support target discovery and validation in genetic heart disease, while clinical development is conducted through global research networks.

FAQ Section

Tenaya focuses on heart diseases caused by genetic mutations or cellular dysfunction, particularly cardiomyopathies that can lead to heart failure. These conditions often involve defects in proteins essential for cardiac muscle contraction.

Many inherited cardiomyopathies arise from mutations in a single gene. Gene therapy offers the possibility of delivering a functional copy of the missing or defective gene directly to heart muscle cells.

This approach could potentially provide long-lasting benefit from a single treatment.

TN-201 is Tenaya’s lead clinical program and targets MYBPC3-associated hypertrophic cardiomyopathy, a genetic condition that can lead to severe heart enlargement and heart failure.

The therapy delivers a functional MYBPC3 gene to cardiac cells using an AAV9 viral vector.

TN-401 is designed for arrhythmogenic right ventricular cardiomyopathy caused by mutations in the PKP2 gene. Like TN-201, it uses an AAV gene-therapy approach to restore normal protein expression in heart tissue.

The company integrates several technologies, including gene therapy, regenerative biology and precision-medicine approaches. This allows Tenaya to target multiple biological mechanisms involved in heart disease.

Tenaya is a clinical-stage biotechnology company. Its lead gene-therapy programs have entered early clinical testing, while additional programs remain in preclinical development.

Key developments include: